TY - JOUR
T1 - LIGHT elevation enhances immune eradication of colon cancer metastases
AU - Qiao, Guilin
AU - Qin, Jianzhong
AU - Kunda, Nicholas
AU - Calata, Jed F.
AU - Mahmud, Dolores L.
AU - Gann, Peter
AU - Fu, Yang Xin
AU - Rosenberg, Steven A.
AU - Prabhakar, Bellur S.
AU - Maker, Ajay V.
N1 - Publisher Copyright:
© 2017 American Association for Cancer Research.
PY - 2017/4/15
Y1 - 2017/4/15
N2 - The majority of patients with colon cancer will develop advanced disease, with the liver being the most common site of metastatic disease. Patients with increased numbers of tumorinfiltrating lymphocytes in primary colon tumors and liver metastases have improved outcomes. However, the molecular factors that could empower antitumor immune responses in this setting remain to be elucidated. We reported that the immunostimulatory cytokine LIGHT (TNFSF14) in the microenvironment of colon cancer metastases associates with improved patient survival, and here we demonstrate in an immunocompetent murine model that colon tumors expressing LIGHT stimulate lymphocyte proliferation and tumor cell-specific antitumor immune responses. In this model, increasing LIGHT expression in the microenvironment of either primary tumors or liver metastases triggered regression of established tumors and slowed the growth of liver metastases, driven by cytotoxic T-lymphocyte-mediated antitumor immunity. These responses corresponded with significant increases in tumor-infiltrating lymphocytes and increased expression of lymphocyte-homing signals in the metastatic tumors. Furthermore, we demonstrated evidence of durable tumor-specific antitumor immunity. In conclusion, increasing LIGHT expression increased T-cell proliferation, activation, and infiltration, resulting in enhanced tumorspecific immune-mediated tumor regressions in primary tumors and colorectal liver metastases. Mechanisms to increase LIGHT in the colon cancer microenvironment warrant further investigation and hold promise as an immunotherapeutic strategy.
AB - The majority of patients with colon cancer will develop advanced disease, with the liver being the most common site of metastatic disease. Patients with increased numbers of tumorinfiltrating lymphocytes in primary colon tumors and liver metastases have improved outcomes. However, the molecular factors that could empower antitumor immune responses in this setting remain to be elucidated. We reported that the immunostimulatory cytokine LIGHT (TNFSF14) in the microenvironment of colon cancer metastases associates with improved patient survival, and here we demonstrate in an immunocompetent murine model that colon tumors expressing LIGHT stimulate lymphocyte proliferation and tumor cell-specific antitumor immune responses. In this model, increasing LIGHT expression in the microenvironment of either primary tumors or liver metastases triggered regression of established tumors and slowed the growth of liver metastases, driven by cytotoxic T-lymphocyte-mediated antitumor immunity. These responses corresponded with significant increases in tumor-infiltrating lymphocytes and increased expression of lymphocyte-homing signals in the metastatic tumors. Furthermore, we demonstrated evidence of durable tumor-specific antitumor immunity. In conclusion, increasing LIGHT expression increased T-cell proliferation, activation, and infiltration, resulting in enhanced tumorspecific immune-mediated tumor regressions in primary tumors and colorectal liver metastases. Mechanisms to increase LIGHT in the colon cancer microenvironment warrant further investigation and hold promise as an immunotherapeutic strategy.
UR - http://www.scopus.com/inward/record.url?scp=85018852769&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85018852769&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-16-1655
DO - 10.1158/0008-5472.CAN-16-1655
M3 - Article
C2 - 28249900
AN - SCOPUS:85018852769
SN - 0008-5472
VL - 77
SP - 1880
EP - 1891
JO - Cancer Research
JF - Cancer Research
IS - 8
ER -